Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Mara Shainheit"'
Autor:
Thomas Davis, Jessica Price, Mark Awad, Ammar Sukari, Roger Cohen, Mark Stein, Przemyslaw Twardowski, Jessica Flechtner, Melissa Johnson, Maura Gillison, Rudy Lackner, Arthur DeCillis, Richard Hernandez, Kevin Mancini, Mara Shainheit, Gabriella Santone, Syukri Shukor, Ece Bicak, Vijetha Vemulapalli, Emily Tjon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/b438e17ae0984433ad0a4a78c3a52d0c
Autor:
Thomas Davis, Jessica Flechtner, Mara Shainheit, Gabriella Santone, Syukri Shukor, Ece Bicak, Li Xue, Emily Tjon, Masoud Golshadi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/bed7ad1f3ae64345b32c3ee75062bac3
Autor:
Thomas Davis, Jessica Price, Ammar Sukari, Roger Cohen, Przemyslaw Twardowski, Jessica Flechtner, Melissa Johnson, Maura Gillison, Rudy Lackner, Arthur DeCillis, Richard Hernandez, Kevin Mancini, Mara Shainheit
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/26d2fd7d8bed4b769e10d720e04ce8c6
Autor:
Thomas Davis, Jessica Flechtner, Mara Shainheit, Devin Champagne, Gabriella Santone, Syukri Shukor, Ece Bicak, Samuel Tipps, Li Xue
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/549af87438a745b4be7db9983a2954c7
Autor:
Przemyslaw Twardowski, Melissa Lynne Johnson, Gabriella Santone, Emily Tjon, Richard Hernandez, Roger B. Cohen, Rudy P. Lackner, Ece Bicak, Syukri Shukor, Mara Shainheit, Jessica Flechtner, Thomas P. Davis, Kevin Mancini, Jessica Price, Maura L. Gillison, Ammar Sukari, Mark M. Awad, Arthur DeCillis, Vijetha Vemulapalli, Mark N. Stein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundGEN-009 adjuvanted personalized cancer vaccine contains up to 20 neoantigens selected by ATLAS™, an ex vivo bioassay screening autologous T-cells for immune responses against both neoantigens and Inhibigens™. Inhibigen-specific T-cells
Autor:
Maura Gillison, Jiaxin Niu, Daniel Olson, Mark Stein, David Aggen, Utkarsh Acharya, Benjamin Creelan, Richard Hernandez, Jessica Price, Kevin J. Mancini, Louisa Dowal, James Foti, Vijetha Vemulapalli, Mara Shainheit, Masoud Golshadi, Raymond D. Stapleton, Jessica B. Flechtner, Thomas A. Davis
Publikováno v:
Cancer Research. 82:CT153-CT153
TiTAN™ is an open-label, multi-center Phase1/2a trial evaluating safety, tolerability, T-cell persistence and proliferation, and clinical activity in patients with some solid tumors. Adoptive T-cell therapies (ACT) have resulted in durable clinical
Autor:
Devin Champagne, Li Xue, Syukri Shukor, Samuel Tipps, Jessica Flechtner, Ece Bicak, Thomas P. Davis, Mara Shainheit, Gabriella Santone
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background ATLASTM is a cell-based bioassay that utilizes a cancer patient‘s own monocyte-derived dendritic cells and CD4+ and CD8+ T cells to screen their mutanome and identify neoantigens that elicit robust anti-tumor T cell responses, as well as
Autor:
Mark M. Awad, Richard Hernandez, Kevin Mancini, Jessica Price, Ammar Sukari, Rudy P. Lackner, Maura L. Gillison, Roger B. Cohen, Jessica Flechtner, Mara Shainheit, Thomas P. Davis, Arthur DeCillis, Przemyslaw Twardowski, Melissa Lynne Johnson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background GEN-009 is an adjuvanted personalized cancer vaccine containing up to 20 neoantigens selected by ATLAS™, an ex vivo bioassay screening autologous T cells to identify both neoantigens as well as Inhibigens™ empirically and without in si
Autor:
Jessica Flechtner, Thomas P. Davis, Li Xue, Ece Bicak, Mara Shainheit, Syukri Shukor, Gabriella Santone, Emily Tjon, Masoud Golshadi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundGEN-009, a personalized vaccine candidate comprised of ATLAS™-prioritized neoantigens combined with Hiltonol®, is currently being evaluated in a Phase 1/2a clinical trial (NCT03633110). ATLAS™ is a cell-based recall assay that, without
Autor:
Kevin Mancini, Jessica Price, Ammar Sukari, Mara Shainheit, Melissa Lynne Johnson, Roger B. Cohen, Jessica Flechtner, Przemyslaw Twardowski, Maura L. Gillison, Vijetha Vemulapalli, Richard Hernandez, Mark N. Stein, Thomas A. Davis, Mark M. Awad
Publikováno v:
Journal of Clinical Oncology. 39:2613-2613
2613 Background: GEN-009 is an adjuvanted personalized cancer vaccine containing up to 20 neoantigens selected by ATLAS, an ex vivo bioassay screening autologous T cells for immune responses against both neoantigens as well as Inhibigens. Inhibigen-s